Literature DB >> 30410215

Dulaglutide for type 2 diabetes.

.   

Abstract

Entities:  

Keywords:  Trulicity; dulaglutide; type 2 diabetes

Year:  2018        PMID： 30410215      PMCID： PMC6202295          DOI： 10.18773/austprescr.2018.052

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  8 in total

1.  Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study.

Authors:  Lawrence Blonde; Johan Jendle; Jorge Gross; Vincent Woo; Honghua Jiang; Jessie L Fahrbach; Zvonko Milicevic
Journal:  Lancet       Date:  2015-05-23       Impact factor: 79.321

2.  Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).

Authors:  Guillermo Umpierrez; Santiago Tofé Povedano; Federico Pérez Manghi; Linda Shurzinske; Valeria Pechtner
Journal:  Diabetes Care       Date:  2014-05-19       Impact factor: 19.112

3.  Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2).

Authors:  Francesco Giorgino; Marian Benroubi; Jui-Hung Sun; Alan G Zimmermann; Valeria Pechtner
Journal:  Diabetes Care       Date:  2015-06-18       Impact factor: 19.112

4.  Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).

Authors:  Carol Wysham; Thomas Blevins; Richard Arakaki; Gildred Colon; Pedro Garcia; Charles Atisso; Debra Kuhstoss; Mark Lakshmanan
Journal:  Diabetes Care       Date:  2014-05-30       Impact factor: 19.112

5.  Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.

Authors:  Kathleen M Dungan; Santiago Tofé Povedano; Thomas Forst; José G González González; Charles Atisso; Whitney Sealls; Jessie L Fahrbach
Journal:  Lancet       Date:  2014-07-10       Impact factor: 79.321

Review 6.  Second steps in managing type 2 diabetes.

Authors:  Carolyn J Petersons
Journal:  Aust Prescr       Date:  2018-10-02

7.  Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).

Authors:  Michael Nauck; Ruth S Weinstock; Guillermo E Umpierrez; Bruno Guerci; Zachary Skrivanek; Zvonko Milicevic
Journal:  Diabetes Care       Date:  2014-04-17       Impact factor: 19.112

Review 8.  Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review.

Authors:  Lin Zhang; Mei Zhang; Yuwei Zhang; Nanwei Tong
Journal:  Sci Rep       Date:  2016-01-08       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.